Table.
Baseline data for participants without diabetes in 20 large statin trials
| Number of patients (statin vs control) | Treatment (active vs control) | Follow-up (years) | Trial population | Age (years) | Diabetes diagnostic criteria* | Weight change data available | Absolute LDL cholesterol lowering at 1 year (%)† | Number of cases of type 2 diabetes on statin (or intensive statin) | Number of cases of type 2 diabetes on control (or low-dose statin) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 4S (1994) | 4242 (2116 vs 2126) | S 10–40 mg vs placebo | 5·2 | Angina or previous MI | 59 | I, II, III | Yes | −1·77 (−37%) | 198 | 193 |
| WOSCOPS (1995) | 5974 (2999 vs 2975) | P 40 mg vs placebo | 4·8 | Male, hypercholesterolaemia, no history of MI | 55 | II, III | Yes | −1·07 (−24%) | 75 | 93 |
| AFCAPS TexCAPS (1998) | 6211 (3094 vs 3117) | L 20–40 mg vs placebo | 5·2 | Average cholesterol concentrations, no CVD | 58 | I, II, III | Yes | −0·94 (−27%) | 72 | 74 |
| LIPID (1998) | 6997 (3496 vs 3501) | P 40 mg vs placebo | 5·9‡ | Hospital admission for unstable angina or previous MI | 62‡ | II, III | Yes | −1·03 (−25%) | 126 | 138 |
| GISSI-Prevenzione (2000) | 3460 (1743 vs 1717) | P 20 mg vs standard care | 1·9 | Recent MI | 59 | III | Yes | −0·35 (−12%) | 96 | 105 |
| LIPS (2001) | 1475 (724 vs 751) | F 80 mg vs placebo | 3·9‡ | Recent percutaneous coronary intervention | 60 | I | No | −0·92 (−27%) | 17 | 14 |
| HPS (2002) | 14 573 (7291 vs 7282) | S 40 mg vs placebo | 5·0 | CVD or diabetes | 65 | I, II | No | −1·29 (−29%) | 335 | 293 |
| PROSPER (2002) | 5023 (2510 vs 2513) | P 40 mg vs placebo | 3·2 | Age 70–82 years with CVD or risk factors | 75 | II, III | Yes | −1·04 (−31%) | 165 | 127 |
| ALLHAT-LLT (2002) | 6087 (3017 vs 3070) | P 40 mg vs no treatment | 4·8 | CHD or CHD risk factors | 66 | III | No | −0·54 (−18%) | 238 | 212 |
| ASCOT-LLA (2003) | 7773 (3910 vs 3863) | A 10 mg vs placebo | 3·3‡ | Hypertension, no CHD | 63 | IV | Yes | −1·07 (−35%) | 154 | 134 |
| PROVE-IT TIMI 22 (2004) | 3395 (1707 vs 1688) | A 80 mg vs P 40 mg | 2·0 | Recent hospital admission for ACS | 58 | I, II, III | Yes | −0·65 (−22%) | 101 | 99 |
| A to Z (2004) | 3504 (1768 vs 1736) | S 40–80 mg vs Placebo −S 20 mg | 2·0‡ | Recent hospital admission for ACS | 60 | I, II | No | −0·30 (−15%) | 65 | 47 |
| TNT (2005) | 7595 (3798 vs 3797) | A 80 mg vs A 10 mg | 5·0 | Stable CHD | 61 | I, II, III | Yes | −0·62 (−22%) | 418 | 358 |
| IDEAL (2005) | 7461 (3737 vs 3724) | A 80 mg vs S 20–40 mg | 4·8‡ | Previous MI | 62 | I, II, III | Yes | −0·55 (−16%) | 240 | 209 |
| SPARCL (2006) | 3803 (1905 vs 1898) | A 80 mg vs placebo | 4·4 | Recent stroke or transient ischaemic attack | 63 | I, II, III§ | Yes | −1·43 (−42%) | 166 | 115 |
| MEGA (2006) | 6086 (3013 vs 3073) | P 10–20 mg vs no treatment | 5·3 | Hypercholesterolaemia, no previous CHD or stroke | 58 | I, II, III | Yes | −0·67 (−17%) | 172 | 164 |
| CORONA (2007) | 3534 (1771 vs 1763) | R 10 mg vs placebo | 2·5 | Systolic heart failure | 73 | I | Yes | −1·63 (−45%) | 100 | 88 |
| JUPITER (2008) | 17 802 (8901 vs 8901) | R 20 mg vs placebo | 1·9‡ | No CVD, no diabetes, hsCRP ≥2·0 mg/L | 66‡ | I, II | Yes | −1·09 (−50%) | 270 | 216 |
| GISSI-HF (2008) | 3378 (1660 vs 1718) | R 10 mg vs placebo | 3·6 | Chronic heart failure | 67 | III | Yes | −0·92 (−35%) | 225 | 215 |
| SEARCH (2010) | 10 797 (5398 vs 5399) | S 80 mg vs S 20 mg | 6·7 | Previous MI | 64 | I | No | −0·39 (−12%) | 625 | 587 |
| Total | 129 170 (64 558 vs 64 612) | .. | 4·2 (1·6) | .. | .. | .. | .. | .. | 3858 | 3481 |
A=atorvastatin. CHD=coronary heart disease. CVD=cardiovascular disease. F=fluvastatin. L=lovastatin. P=pravastatin. MI=myocardial infarction. R=rosuvastatin. S=simvastatin.
*
Diagnostic criteria: I=adverse event report or physician report; II=glucose lowering therapy; III=raised fasting plasma glucose (≥7·0 mmol/L) on at least one occasion.
†
Change in lipid values at 1 year except for SPARCL (average difference during trial) and CORONA (difference at 3 months).
‡
Median values.
§
Included criterion that diagnostic raised fasting plasma glucose must be at least 2·0 mmol/L higher than baseline glucose.